ClinicalTrials.gg
RecruitingNCT07083154Updated Sep 2, 2026

Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)

A Phase 3 interventional study of Mazdutide and Placebo in Dementia, Mild, Mild Cognitive Impairment and Type 2 Diabetes, sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. Recruiting at 8 sites in China. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
50 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 74 studies in Dementia with a site in China — 39 open to participants now, 43 under way, 3 of them phase 3. Dementia · China.

Planned enrollment
10th of 44
420 · median 144
Started
2025
with 7 others
Phase 3
6 of 74
2 open now
Primary completion
2029-08
later than 28 of 42 live
Registered
56th of 74
by date

Among the 74 studies in Dementia with a site in China, this one is the 10th largest by planned enrollment of the 44 interventional ones that give a count, is one of 8 that started in 2025, is one of 6 in phase 3, reaches primary completion later than 28 of the 42 other live ones, and was the 56th registered.

Dementia

2,374 studies on the registry are indexed under Dementia; 573 are open to participants now.

Browse Dementia studies →

Open to participants now

39 of the 74 studies in Dementia with a site in China are open now. Recruiting first, the newest first:

33 more — sign in →

All 39 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 383 Dementia studies recruiting now, 244 (64%) set no upper age limit and 25 (7%) stop at 75 or younger; 16 take children under 18; 164 take healthy volunteers.

This study: 50 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies in Dementia with a site in China, or all of them as a file.
02

Study summary

The LIGHT-COG study is a 76-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial evaluating the efficacy and safety of mazdutide in 420 participants with type 2 diabetes (T2D) and early-stage cognitive impairment, defined as mild cognitive impairment (MCI) or mild dementia. Participants are randomized 1:1 to receive once-weekly subcutaneous mazdutide, with dose escalation according to the protocol, or matching placebo, in addition to background glucose-lowering therapy. The primary objective is to determine whether 76 weeks of mazdutide treatment can slow cognitive and functional decline compared with placebo in this population.

Read the detailed description

The LIGHT-COG study is a 76-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial evaluating the efficacy and safety of mazdutide in 420 participants with T2D and early-stage cognitive impairment (MCI or mild dementia). Participants will be randomized 1:1 to receive once-weekly subcutaneous mazdutide or matching placebo in addition to background glucose-lowering therapy. Mazdutide will be initiated at 2.0 mg once weekly and up-titrated to 4.0 mg, with further escalation to 6.0 mg permitted according to prespecified glycemic, weight, tolerability, and safety criteria. The primary outcome is the between-group difference in change from baseline to Week 76 in the Integrated Alzheimer's Disease Rating Scale (iADRS) score. Secondary outcomes include cognitive and functional measures, structural brain MRI measures, and metabolic outcomes. Exploratory outcomes include blood-based biomarkers, amyloid PET/MRI, CDR-based clinical stage progression, resting-state functional connectivity, and additional cardiometabolic and body-composition measures. Safety and tolerability will be assessed throughout the treatment period.

Participants will generally continue their background glucose-lowering therapy during the trial. If glycemic control remains inadequate after titration to the highest tolerated study dose, additional glucose-lowering therapy may be initiated at the investigator's discretion. Permitted therapies include insulin glargine, metformin, gliclazide sustained-release, and acarbose. Study treatment may be interrupted, dose-reduced, or permanently discontinued for intolerance, adverse events, persistent glycemic instability, or other medical or safety reasons.

03

Conditions studied

  • Dementia, Mild
  • Mild Cognitive Impairment
  • Type 2 Diabetes

Keywords

  • Type 2 Diabetes
  • Mild Dementia
  • Mild Cognitive Impairment
  • Dual GLP-1/Glucagon Receptor Agonist
  • Early-Stage Cognitive Impairment
04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of type 2 diabetes according to the American Diabetes Association criteria;
  2. Aged 50-75 years (inclusive), male or female.
  3. Early-stage cognitive impairment (defined as mild cognitive impairment or mild dementia), with all of the following:

    1. score >20 and \<27,
    2. CDR global score 0.5-1.0 (inclusive), with a CDR memory subscore ≥0.5,
    3. A history of gradual and progressive cognitive decline for at least 6 months, reported by the participant or an informant.
  4. Stable glycemic control regimen for ≥3 months prior to screening, meeting one of the following:

    1. Lifestyle/dietary intervention alone (no glucose-lowering drugs),
    2. Oral antidiabetic drugs (OADs), with or without once-daily basal insulin.
  5. 7.0-9.0% (inclusive) at screening.
  6. ≥20 kg/m², with stable weight (fluctuation \<5%) for ≥3 months.
  7. Stable treatment regimen for cognitive impairment for at least 3 months prior to screening and commit to its continuation throughout the study period, meeting one of the following criteria:

    1. No treatment: Not receiving any pharmacological or non-pharmacological interventions for cognitive impairment;
    2. Non-pharmacological therapy only: Engaged exclusively in non-drug interventions (e.g., cognitive training);
    3. Pharmacological therapy: Using approved symptomatic cognitive-enhancing medications (e.g., cholinesterase inhibitors, NMDA receptor antagonists), excluding disease-modifying therapies for Alzheimer's disease (AD).
  8. Ability to comply with systematic cognitive and functional assessments.
  9. Fully understands the trial protocol, voluntarily signs the form (ICF), and agrees to adhere to all study requirements and restrictions.

Exclusion criteria

Exclusion Criteria:

  1. Known or suspected neurodegenerative disorders other than AD that are likely to be a major cause of cognitive impairment or to interfere with cognitive assessment, including but not limited to frontotemporal dementia and related syndromes, dementia with Lewy bodies, Parkinson's disease with cognitive impairment or dementia, progressive supranuclear palsy, corticobasal degeneration, multiple system atrophy, and Huntington's disease;
  2. Current diagnosis of a poorly controlled or unstable psychiatric disorder (including but not limited to schizophrenia, bipolar disorder, major depressive disorder, generalized anxiety disorder, personality disorders, etc.), which, in the investigator's judgment, may interfere with study assessments, affect treatment compliance, or increase participant risk.
  3. With a Patient Health Questionnaire-9 (PHQ-9) score ≥10 at screening, or a Generalized Anxiety Disorder Scale-7 (GAD-7) score ≥10 at screening.
  4. Ischaemic or haemorrhagic stroke, , or epileptic seizure within 3 months before screening; or other current or central nervous system disorders or injuries likely to impair cognitive function or interfere with cognitive assessment, including but not limited to central nervous system infection, intracranial tumour, multiple sclerosis, metabolic encephalopathy, neurological disorders related to malnutrition, or severe traumatic brain injury;
  5. Acute hyperglycemic/hypoglycemic events within 1 year, including: Diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic state (HHS), and Hypoglycemic coma
  6. Use of GLP-1 receptor agonists, dual GIP/GLP-1 receptor agonists, dual GLP-1/glucagon receptor agonists, or triple GIP/GLP-1/glucagon receptor agonists within 3 months before screening;
  7. Regular use (>2 doses/week) of moderate-to-strong anticholinergic drugs within 4 weeks prior to screening; Use within 3 months prior to screening of: Anti-Parkinsonian drugs, Antiepileptic drugs, Antipsychotics, Morphine and opioid analgesics (Exemption: Short-term use [\<5 days] for surgery/acute injury, if completed >4 weeks before screening); Use within 4 weeks prior to screening of: CNS stimulants; Medical/recreational cannabis, cannabinoids, or cannabidiol (CBD).a. Moderate/high anticholinergics, antiparkinsonian/antiepileptic drugs.
  8. Alcohol abuse (defined as >21 units/week for men or >14 units/week for women; 1 unit = 360 mL beer, 150 mL wine, or 45 mL spirits).
  9. Medical history of:

    1. Medullary thyroid carcinoma (MTC), pancreatitis
    2. Multiple endocrine neoplasia type 2 (MEN2)
    3. Gallbladder/biliary disease, severe gastrointestinal disorders, or bowel resection
    4. Active
  10. Uncontrolled or potentially unstable diabetic retinopathy/maculopathy.
  11. Severe organ dysfunction, including:

    1. /AST >3× (ULN);
    2. \<45 mL/min/1.73m² (CKD-EPI equation);
    3. History of unstable angina or myocardial infarction within 3 months before screening, or current heart failure of class II or higher.
  12. Known/suspected to the product or related compounds
  13. Pregnancy, lactation, or women of not using highly effective .
  14. MRI (e.g., metal implants, claustrophobia).
  15. Participation in other clinical trials within 3 months, involving an investigational medicinal product or enrollment in any other type of medical research judged not to be scientifically or medically compatible with this study.
  16. Any other condition deemed by the investigator to compromise safety or interfere with study assessments.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
420 participants (estimated)

Study arms

  • Experimental
    Mazdutide group

    Participants will receive once-weekly subcutaneous mazdutide, starting at 2.0 mg and titrated to 4.0 mg, with optional escalation to 6.0 mg according to prespecified criteria. Participants unable to tolerate a given dose will remain on the highest tolerated dose, in addition to background glucose-lowering therapy.

    Drug: Mazdutide

  • Placebo comparator
    Placebo group

    Participants will receive weekly subcutaneous injections of matched placebo, in addition to their existing glucose-lowering therapy.

    Drug: Placebo

Interventions

  • Mazdutide is administered once weekly by subcutaneous injection using a prefilled autoinjector pen, preferably on the same day each week. Treatment is initiated at 2.0 mg once weekly and up-titrated to 4.0 mg once weekly during Weeks 4-12 according to individual tolerability. After at least 4 weeks at 4.0 mg, further escalation to 6.0 mg once weekly may be considered if prespecified criteria are met. Participants who are unable to tolerate a given dose may continue treatment at the highest tolerated dose. The total treatment duration is 76 weeks.

    Also known as: IBI362

  • DrugPlacebo

    Matching placebo is administered once weekly by subcutaneous injection using a prefilled autoinjector pen. Participants will undergo the same blinded titration and dose-adjustment schedule as the mazdutide group, including corresponding 2.0 mg, 4.0 mg, and, where applicable, 6.0 mg dosing levels. Participants unable to tolerate a given dosing level may remain at the highest tolerated level. The total treatment duration is 76 weeks.

06

What researchers measure

Primary outcomes

  1. Integrated Alzheimer's Disease Rating Scale (iADRS) Score Change

    The change in Integrated Alzheimer's Disease Rating Scale (iADRS) scores from baseline to Week 76 will be compared between the treatment group and the placebo group to assess the drug's potential to improve or slow cognitive decline. iADRS is a composite endpoint that integrates cognitive and functional assessments (scores from Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog13) and Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living(ADCS-iADL)) to generate a total score (range: 0-144). The calculation formula is: iADRS score = (85 - ADAS-Cog13 score) + ADCS-iADL score A lower score indicates more severe cognitive and functional impairment.

    Time frame: From Baseline to Week 76

Secondary outcomes

  1. Mini-Mental State Examination (MMSE) Score Change

    The change in Mini-Mental State Examination (MMSE) scores from baseline to Week 76 will be compared between the treatment group and the placebo group to assess the drug's potential to improve or slow cognitive decline. It assesses multiple cognitive domains, including orientation, memory, attention and calculation, recall ability, language, and visuospatial skills. The total score ranges from 0 to 30, with higher scores indicating better cognitive function.

    Time frame: From Baseline to Week 76

  2. Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) Score Change

    The change in Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) scores from baseline to Week 76 will be compared between the treatment group and the placebo group to assess the drug's potential to improve or slow cognitive decline. The score ranges from 0 to 18, with higher scores indicating greater severity of cognitive and functional impairment.

    Time frame: From Baseline to Week 76

  3. Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog13) Score Change

    The change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog13) scores from baseline to Week 76 will be compared between the treatment group and the placebo group to assess the drug's potential to improve or slow cognitive decline. The score ranges from 0 to 85, with higher scores indicating more significant cognitive impairment.

    Time frame: From Baseline to Week 76

  4. Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-iADL) Score Change

    The change in Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-iADL) scores from baseline to Week 76 will be compared between the treatment group and the placebo group to assess the drug's potential to improve or slow functional decline. The total score ranges from 0 to 59, with lower scores indicating more severe functional impairment.

    Time frame: From Baseline to Week 76

  5. Change in Total Brain Volume

    The change in total brain volume evaluated by structural MRI from baseline to Week 76 will be compared between the treatment group and the placebo group.

    Time frame: From Baseline to Week 76

  6. Change in Total White Matter Lesion Volume

    The change in total white matter lesion volume evaluated by sturctural MRI from baseline to Week 76 will be compared between the treatment group and the placebo group.

    Time frame: From Baseline to Week 76

  7. Change in hippocampal volume

    Change from baseline to Week 76 in hippocampal volume assessed by structural brain MRI.

    Time frame: From Baseline to Week 76

  8. Change in entorhinal cortex volume

    Change from baseline to Week 76 in entorhinal cortex volume assessed by structural brain MRI.

    Time frame: From Baseline to Week 76

  9. Change in Body Weight

    Change in body weight from baseline to weeks 76.

    Time frame: From Baseline to Week 76.

  10. Change in Body Mass Index (BMI)

    Change in BMI from baseline to week 76.

    Time frame: From Baseline to Week 76.

  11. Change in Glycated Haemoglobin (HbA1c) Levels

    Change in HbA1c levels from baseline to week 76

    Time frame: From Baseline to Week 76

  12. Change in Fasting Plasma Glucose Levels

    Change in fasting plasma glucose levels from baseline to week 76

    Time frame: From Baseline to Week 76

  13. Change in 2-hour Postprandial Plasma Glucose Levels

    Change in fasting plasma glucose levels from baseline to week 76

    Time frame: From Baseline to Week 76

Other outcomes

  1. Incidence of Treatment-emergent Adverse Events

    Difference in incidence of treatment-emergent adverse events during the trial period (treatment vs. placebo).

    Time frame: From Baseline to Week 76

  2. Incidence of Treatment-emergent Serious Adverse Events

    Difference in incidence of serious adverse events during the trial period (treatment vs. placebo).

    Time frame: From Baseline to Week 76

  3. Change in Blood-based biomarkers related to AD pathology and neurodegeneration

    The change in blood-based biomarkers related to AD pathology and neurodegeneration (includingAmyloid-β (Aβ42/40 ratio), Phosphorylated tau (p-tau217), Glial fibrillary acidic protein (GFAP), and Neurofilament light chain (NfL), etc.)evaluated by Simoa from baseline to Week 76 will be compared between the treatment group and the placebo group.

    Time frame: From Baseline to Week 76

  4. Change in brain Aβ burden assessed using [¹⁸F]florbetapir amyloid PET/MRI in participants undergoing this assessment

    The change in brain Aβ burden assessed using \[¹⁸F\]florbetapir amyloid PET/MRI in participants undergoing this assessment from baseline to Week 76 will be compared between the treatment group and the placebo group.

    Time frame: From Baseline to Week 76

  5. Change in body composition

    The change in body composition assessed using dual-energy X-ray absorptiometry from baseline to Week 76 will be compared between the treatment group and the placebo group.

    Time frame: From Baseline to Week 76

  6. Change in liver fat and fibrosis

    The change in liver fat and fibrosis assessed using transient elastography from baseline to Week 76 will be compared between the treatment group and the placebo group.

    Time frame: From Baseline to Week 76

  7. Change in additional cardiometabolic parameters

    The change in additional cardiometabolic parameters (including waist circumference, hip circumference, waist-to-hip ratio, blood pressure, lipid profile, pancreatic β-cell function, and insulin resistance) from baseline to Week 76 will be compared between the treatment group and the placebo group.

    Time frame: From Baseline to Week 76

  8. Changes in regional structural brain MRI measures

    Changes from baseline to Week 76 in exploratory regional structural MRI measures, including total grey and white matter volumes, lobar grey matter volumes, volumes of subcortical grey matter structures, and volumes and cortical thickness of other prespecified neurodegeneration-sensitive regions.

    Time frame: From Baseline to Week 76

07

Study locations

6 of 8 sites recruiting
  • Department of Endocrinology, Xiangya Hospital of Central South University
    Changsha, Hunan 410008, China
    Not yet recruiting
    • Jing Wu, MD, PhD · Contact
    • Jing Wu, MD, PhD · Principal investigator
  • Department of Endocrinology, Changzhou No.2 People's Hospital
    Changzhou, Jiangsu, China
    Recruiting
    • Huijie Yang, MD · Contact
    • Xinhua Ye, MD, PhD · Principal investigator
    • Huijie Yang, MD · Sub investigator
  • Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University
    Nanjing, Jiangsu 210000, China
    Recruiting
    • Jindan Wu, MD, PhD · Contactwujindandan@sina.com · 86-025-52271000
    • Jindan Wu, MD, PhD · Principal investigator
    • Peng Zhang, MD · Sub investigator
  • Department of Endocrinology, Endocrine and Metabolic Disease Medical Center,Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
    Nanjing, Jiangsu 210008, China
    Recruiting
    • Yan Bi, MD, PhD · Contactbiyan@nju.edu.cn · 86-25-83-105302
    • Zhou Zhang, MD, PhD · Contactzhangzhou@smail.nju.edu.cn · 86-25-83-105302
    • Yan Bi, MD, PhD · Principal investigator
    • Zhou Zhang, MD, PhD · Sub investigator
  • Department of Endocrinology, Jiangsu Province Hospital of Traditional Chinese Medicine
    Nanjing, Jiangsu, China
    Recruiting
    • Yueting Zhao, MD · Contact
    • Yueting Zhao, MD · Principal investigator
  • The Second Affiliated Hospital of Dalian Medical University
    Dalian, Liaoning, China
    Not yet recruiting
    • Haixia Liu, MD, PhD · Contact
    • Haixia Liu, MD, PhD · Principal investigator
  • Department of Endocrinology, Shanghai General Hospital
    Shanghai, Shanghai Municipality 200080, China
    Recruiting
    • Fang Fang, MD, PhD · Contact
    • Fang Fang, MD,PhD · Principal investigator
  • Department of Endocrinology, Huadong Hospital Affiliated to Fudan University
    Shanghai, 200040, China
    Recruiting
    • Bin Lu, MD, PhD · Contact
    • Bin Lu, MD, PhD · Principal investigator
    • Cuiping Jiang, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — Availability: De-identified participant data may be timely shared with qualified researchers upon request, subject to review and approval. Access Conditions: Data requests require a valid research proposal and signed data use agreement. Approval is contingent on compliance with applicable laws and ethical guidelines. Timing: Data will become available after study completion and primary publication for 3 years. Restrictions: Certain data types may be excluded due to privacy or regulatory requirements. Contact: Requests should be submitted to the study sponsor for consideration.

Supporting information: Study protocol, Informed consent form

Time frame: Data will become available after study completion and primary publication for 3 years.

Access criteria: Data requests require a valid research proposal and signed data use agreement. Approval is contingent on compliance with applicable laws and ethical guidelines.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Aug 2029, 46 months after the start.

Of 34 phase 3 interventional studies under Dementia, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's planned 46 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2025
First posted
Jul 24, 2025
StartActual
Sep 27, 2025
Primary completionEst.
Aug 1, 2029
CompletionEst.
Aug 1, 2029
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07083154
Collaborators
Nanjing First Hospital, Nanjing Medical University, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Xiangya Hospital of Central South University, Huadong Hospital, Jiangsu Province Hospital of Traditional Chinese Medicine, Changzhou No.2 People's Hospital, The Second Affiliated Hospital of Dalian Medical University
Responsible party
Yan Bi (Chief Physician, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School) — Principal investigator
First posted
Jul 24, 2025
Start date
Sep 27, 2025
Primary completion
Aug 1, 2029 (estimated)
Completion
Aug 1, 2029 (estimated)
Last update
Sep 2, 2026

Study contacts

Yan Bi, MD, PhD
Contact
biyan@nju.edu.cn
6-25-83-105302.
Zhou Zhang, MD, PhD
Contact
zhangzhou@smail.nju.edu.cn
86-25-83-105302
Yan Bi, MD, PhD
principal investigator · Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mazdutide

Start the discussion